Moderate To Severe Atopic Dermatitis clinical trials

Explore recruiting moderate to severe atopic dermatitis clinical trials.

Recruiting moderate to severe atopic dermatitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate To Severe Atopic Dermatitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis

Poland, Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

France, Estonia, Croatia, Finland, Denmark, Bulgaria +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

Netherlands, Denmark, Hungary, Ireland, Portugal, Italy +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

LP0162-1335: A single (assessor) blinded, randomized, parallel-group, monotherapy trial to evaluate the pharmacokinetics and safety of tralokinumab in children (age 6 to <12 years) with moderate to-severe atopic dermatitis. - TRAPEDS 1 (TRAlokinumab PEDiatric trial no. 1).

France, Spain, Netherlands, Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof of Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Moderate To Severe Atopic Dermatitis trials by city

Moderate To Severe Atopic Dermatitis in Toronto Moderate To Severe Atopic Dermatitis in Vancouver Moderate To Severe Atopic Dermatitis in Montreal Moderate To Severe Atopic Dermatitis in Calgary Moderate To Severe Atopic Dermatitis in Edmonton Moderate To Severe Atopic Dermatitis in Ottawa Moderate To Severe Atopic Dermatitis in Winnipeg Moderate To Severe Atopic Dermatitis in Quebec City Moderate To Severe Atopic Dermatitis in Hamilton Moderate To Severe Atopic Dermatitis in Kitchener Moderate To Severe Atopic Dermatitis in London Moderate To Severe Atopic Dermatitis in Halifax Moderate To Severe Atopic Dermatitis in New York Moderate To Severe Atopic Dermatitis in Los Angeles Moderate To Severe Atopic Dermatitis in Chicago Moderate To Severe Atopic Dermatitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease